Literature DB >> 20453687

Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers.

Tawee Tanvetyanon1, Lary Robinson, K Eric Sommers, Eric Haura, Jongphil Kim, Soner Altiok, Gerold Bepler.   

Abstract

BACKGROUND: Multiple synchronous non-small cell lung cancers (NSCLCs) without extrathoracic metastasis are relatively uncommon. Some patients are treated as metastatic disease by chemotherapy alone; others are treated as multiple primary cancers by surgery. For those undergoing surgery, limited information exists on the relationship between tumor size and survival.
METHODS: We retrospectively reviewed medical records of patients with resection of at least two synchronous NSCLC located in > or =2 lobes during 1997-2008. Those with only satellite nodules in single lobe were excluded. Cox proportional hazard model was used to examine the prognostic significance of tumor size in the context of other clinical parameters including tumor stage, nodal stage, age, gender, laterality, histology, and pneumonectomy.
RESULTS: There were 116 patients: 57 patients had cancers distributed in one lung and 59 in both lung. Overall, 186 thoracotomies were performed, with a 90-day mortality rate of 2.6%. The median overall survival was 65.1 months (95% confidence interval [CI]: 49.2-83.7). The median size of the largest tumor and the median sum of tumor sizes were 3.0 and 4.5 cm, respectively. Both were a significant predictor of survival: hazard ratios per centimeter increase where 1.17 (95% CI: 1.06-1.30, p = 0.003) and 1.15 (95% CI: 1.05-1.26, p = 0.003), respectively. Multivariable regression analysis identified tumor size and lung function as independent survival predictors.
CONCLUSION: Among patients with resected multiple synchronous NSCLC, tumor size is an independent predictor of survival. The size of the largest tumor performs slightly better than the sum of tumor sizes in the survival prediction; however, both are much better than the American Joint Committee on Cancer stage for this purpose.

Entities:  

Mesh:

Year:  2010        PMID: 20453687     DOI: 10.1097/JTO.0b013e3181dd0fb0

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  10 in total

1.  Survival rate and prognostic factors of surgically resected clinically synchronous multiple primary non-small cell lung cancer and further differentiation from intrapulmonary metastasis.

Authors:  Fei Xiao; Deruo Liu; Yongqing Guo; Bin Shi; Zhiyi Song; Yanchu Tian; Zhenrong Zhang; Chaoyang Liang
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

2.  Coexistent Non-Small Cell Carcinoma and Small Cell Carcinoma in a Patient Presenting with Hyponatremia.

Authors:  Mitchell D Ross; Sreeja Biswas Roy; Pradnya D Patil; Jasmine L Huang; Nitika Thawani; Ralph Drosten; Tanmay S Panchabhai
Journal:  Case Rep Pulmonol       Date:  2018-02-20

3.  [Synchronous Multiple Primary Lung Cancer Dignosed 
by Different Phenotype-genotype: A Case Report and Literature Review].

Authors:  Xin Li; Zhirong Zhang; Yili Fu; Jinbai Miao; Bin Hu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-12-20

4.  Clinical outcomes of stereotactic body radiotherapy for de novo pulmonary tumors in patients with completely resected early stage non-small cell lung cancer.

Authors:  Qianqian Zhao; Gang Chen; Luxi Ye; Zhaochong Zeng; Shiming Shi; Jian He
Journal:  Cancer Manag Res       Date:  2018-11-28       Impact factor: 3.989

5.  Characteristics and prognosis of synchronous multiple primary lung cancer after surgical treatment: A systematic review and meta-analysis of current evidence.

Authors:  Hongtao Tie; Jun Luo; Rui Shi; Zhenhan Li; Dan Chen; Qingchen Wu
Journal:  Cancer Med       Date:  2020-12-10       Impact factor: 4.452

6.  Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Durvalumab.

Authors:  Sergey Gavrilov; Kirill Zhudenkov; Gabriel Helmlinger; James Dunyak; Kirill Peskov; Sergey Aksenov
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-12-21

7.  Tumor burden of lung metastases at initial staging in breast cancer patients detected by artificial intelligence as a prognostic tool for precision medicine.

Authors:  Madison R Kocher; Jordan Chamberlin; Jeffrey Waltz; Madalyn Snoddy; Natalie Stringer; Joseph Stephenson; Jacob Kahn; Megan Mercer; Dhiraj Baruah; Gilberto Aquino; Ismail Kabakus; Philipp Hoelzer; Pooyan Sahbaee; U Joseph Schoepf; Jeremy R Burt
Journal:  Heliyon       Date:  2022-02-15

8.  Unusual synchronous lung tumors: mucoepidermoid carcinoma and mucinous adenocarcinoma.

Authors:  Ana M Ponea; Creticus P Marak; Ying Sun; Achuta Kumar Guddati; Amit S Tibb
Journal:  Case Rep Oncol Med       Date:  2014-02-18

9.  Surgical Outcomes of Synchronous Multiple Primary Non-Small Cell Lung Cancers.

Authors:  Zhirong Zhang; Shugeng Gao; Yousheng Mao; Juwei Mu; Qi Xue; Xiaoli Feng; Jie He
Journal:  Sci Rep       Date:  2016-06-02       Impact factor: 4.379

10.  SUVmax and Tumor Size Predict Surgical Outcome of Synchronous Multiple Primary Lung Cancers.

Authors:  Hsian-He Hsu; Kai-Hsiung Ko; Yu-Ching Chou; Lin-Fan Lin; Wen-Chuan Tsai; Shih-Chun Lee; Hung Chang; Tsai-Wang Huang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.